Table 2.
Characteristics of studies included in the meta-analysis conducted by Yan et al. [30] for the association of low-dose methotrexate exposure and melanoma
| First author (Year) | Design | Cases/ Participants |
Duration of study | Mean Age (years) | Female (No, %) | Methotrexate | Comparator |
|---|---|---|---|---|---|---|---|
| Breedveld (2006) | RCT | 1/531 | 24 months | NA | 74.5 | Methotrexate | Adalimumab |
| Klareskog (2004) | RCT | 1/340 | 12 months | 53.0 | 77.0 | Methotrexate | Etanercept |
| Puéchal (2016) | RCT | 1/115 | 12 months | 59.8 | 51.6 | Methotrexate | Azathioprine |
| Vanni (2020) | RCT | 9/3676 | 27.6 months | 65.5 | 18.8 | Methotrexate | Unspecified |
| Van Vollenhoven (2020) | RCT | 1/945 | 6 months | 53.7 | 76.0 | Methotrexate | Upadacitinib |
| Westhovens (2021) | RCT | 1/626 | 12 months | 53.0 | 77.0 | Methotrexate | Filgotinib |
| Berge (2020) | Case-control study | 12,106/130,670 | NA | NA | NA | Methotrexate | Unspecified |
| Polesie (2020) | Case-control study | 395/4345 | NA | NA | 55.2 | Methotrexate | Unspecified |
| Chaparro (2017) | Cohort study | 10/5577 | 16.4 months | NA | 47.3 | Methotrexate | Thiopurine |
| Polesie (2017) | Cohort study | 3097/606,259 | 6 months | 57.4 | 62.8 | Methotrexate | Unspecified |
| Polesie (2017) | Cohort study | 654/7911 | 6 months | 59.3 | 63.7 | Methotrexate | Unspecified |
| Yan (2021) | Cohort study | 366/19,114 | NA | 74.0 | 56 | Methotrexate | Unspecified |